Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Edwards Lifesciences Corporation (EW) — XLV Health Care · S&P 500 Profile |愛德華生命科學介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Edwards Lifesciences Corporation (EW) — Business, History & S&P 500 Profile |愛德華生命科學介紹

Edwards Lifesciences company profile · structural heart & critical care medical devices · history · financial snapshot · S&P 500 rank #222 · 愛德華生命科學公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 30, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$53.03B
Oct 30, 2026 · Slickcharts (frozen benchmark)
S&P 500 WEIGHT
0.08%
Rank #222 · Oct 30, 2026 (Slickcharts)
FY2025 REVENUE
$6.07B
+11.5% YoY
FY2025 NET INCOME
$1.07B
FY2025 net income

SNAPSHOT

TickerEW (NYSE)
CompanyEdwards Lifesciences Corporation
GICS sector / industryHealth Care (XLV) / Health Care Equipment & Supplies
S&P 500 rank (by weight)#222 · 0.08% (Oct 30, 2026)
Sector rank (by market cap)#28 in Health Care (Oct 30, 2026)
Share price (frozen benchmark)$92.01 (Oct 30, 2026)
HeadquartersIrvine, California
Founded1958 (by Miles Lowell Edwards)
CEOBernard J. Zovighian (CEO)
Employeesabout 16,000 (2025)
Market cap$53.03B (Oct 30, 2026)

WHAT IT DOES

Edwards Lifesciences is a medical technology company focused on structural heart disease and critical care monitoring. Its flagship products are transcatheter heart valves — principally the SAPIEN platform — plus surgical heart valves, transcatheter mitral and tricuspid therapies, and monitoring systems used in operating rooms and intensive care units.

The model is procedure-driven: each valve implant generates device revenue, and growth follows procedure volumes, new indications and geographic expansion. FY2025 net sales were $6,068M, up 11.5% from $5,440M, gross profit was $4,733M, operating income was $1,636M and net income was $1,074M.

FY2024 net income of $4,175M was inflated by a large one-time gain, so the FY2025 decline in net income is not a business decline — it is the absence of that gain. Year-over-year net income comparisons must carry that context.

BUSINESS SEGMENTS — FY2025 NET SALES

SegmentRevenueShareYoY
Transcatheter Heart Valve Therapy———
Surgical Structural Heart———
Transcatheter Mitral and Tricuspid Therapies———
Segment revenue split not stated in the sources used; units are listed qualitatively, with revenue, share and YoY shown as —. Do not read a split from this table.

HISTORY

YearMilestone
1958Founded by Miles Lowell Edwards, inventor of the first medically proven artificial heart valve
1960The first Starr-Edwards mitral valve is successfully placed in a patient
1985Acquired by Baxter International
2000Spins off from Baxter and lists on the New York Stock Exchange
2023Bernard J. Zovighian becomes CEO
2025FY2025 net sales reach $6,068M, up 11.5%

COMPETITIVE POSITION

  • TAVR leadership — the SAPIEN platform leads transcatheter aortic valve replacement.
  • Clinical evidence — decades of trial data support adoption and reimbursement.
  • Procedure growth — aging populations expand the treatable patient pool.
  • Competition — Medtronic and Abbott contest structural heart markets.
  • Direct sales force — specialist teams support hospitals through complex procedures.

FINANCIAL SNAPSHOT — FY2025

Net sales$6,068M (+11.5% YoY)
Gross profit$4,733M
Operating income$1,636M
Net income$1,074M
Prior-year net income (FY2024)$4,175M (includes a large one-time gain)
Source: Edwards Lifesciences FY2025 results (fiscal year ended Dec 31, 2025). FY2024 net income is shown only to explain the year-over-year comparison: it includes a large one-time gain and is not a run-rate figure. Employee figure is the FY2025 count.

KEY RISKS

  • Procedure volumes — hospital capacity and referral patterns set implant counts.
  • Competition — Medtronic and Abbott develop competing valve platforms.
  • Regulatory and trial risk — new indications need trial success and approval.
  • Reimbursement — payer coverage decisions affect adoption.
  • Manufacturing concentration — specialist valve production is hard to replace quickly.

WHY IT MATTERS FOR THE S&P 500

Edwards is the S&P 500's structural-heart name: at a 0.08% index weight and #28 in Health Care by market cap, it is the index's main exposure to transcatheter heart valves.

Its procedure growth is a standing read on cardiovascular intervention demand — valve volumes move with aging and diagnosis before they show up in hospital procedure revenue.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 30, 2026 close)
FinancialsEdwards Lifesciences FY2025 results (fiscal year ended Dec 31, 2025), company profile sources
Sector classificationGICS (Health Care Equipment & Supplies) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

EW

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼EW(NYSE)
公司Edwards Lifesciences Corporation
GICS 板塊/行業醫療保健(XLV)/醫療保健設備與用品
標普500排名(按權重)#222 · 0.08%(2026 年 10 月 30 日)
板塊內排名(按市值)醫療保健第 #28(2026 年 10 月 30 日)
股價(凍結基準)$92.01(2026 年 10 月 30 日)
總部美國加州爾灣
成立1958 年(Miles Lowell Edwards 創辦)
行政總裁Bernard J. Zovighian(行政總裁)
員工約 16,000(2025 年)
市值$53.03B(2026 年 10 月 30 日)

業務概覽

愛德華生命科學是一家醫療科技公司,專注於結構性心臟病與重症監護監測。旗艦產品為經導管心臟瓣膜——主要為 SAPIEN 平台——以及外科心臟瓣膜、經導管二尖瓣與三尖瓣療法,及手術室與深切治療部使用的監測系統。

其模式以手術量驅動:每次瓣膜植入帶來裝置收入,增長跟隨手術量、新適應症與地區擴張。FY2025 淨銷售額為 $6,068M,同比增長 11.5%(FY2024 為 $5,440M),毛利為 $4,733M,營業利潤為 $1,636M,淨利潤為 $1,074M。

FY2024 淨利潤 $4,175M 因一項大額一次性收益而膨脹,故 FY2025 淨利潤下跌並非業務下滑——而是該收益不再出現。同比淨利潤比較須附此背景。

業務板塊 — FY2025

板塊收入佔比同比
經導管心臟瓣膜療法———
外科結構性心臟———
經導管二尖瓣與三尖瓣療法———
板塊收入拆分未見於所用來源;本表只作定性列示,收入、佔比與同比均記為 —,請勿據此推斷拆分。

歷史沿革

年份里程碑
1958由首個人工心臟瓣膜醫學驗證發明者 Miles Lowell Edwards 創辦
1960首個 Starr-Edwards 二尖瓣成功植入患者體內
1985被 Baxter International 收購
2000由 Baxter 分拆並在紐約證券交易所上市
2023Bernard J. Zovighian 出任行政總裁
2025FY2025 淨銷售額達 $6,068M,同比增長 11.5%

競爭地位

  • 經導管主動脈瓣置換領先——SAPIEN 平台在經導管主動脈瓣置換居先。
  • 臨床證據——數十年的試驗數據支持採用與報銷。
  • 手術增長——人口老齡化擴大可治療患者群體。
  • 競爭——Medtronic 與 Abbott 爭奪結構性心臟市場。
  • 直銷團隊——專業團隊在複雜手術中支援醫院。

財務快照 — FY2025

淨銷售額$6,068M(同比 +11.5%)
毛利$4,733M
營業利潤$1,636M
淨利潤$1,074M
上年度淨利潤(FY2024)$4,175M(含大額一次性收益)
來源:愛德華生命科學 FY2025 業績(財政年度截至 2025 年 12 月 31 日)。FY2024 淨利潤僅為解釋同比比較而列:其含大額一次性收益,並非常態數字。員工數字為 FY2025 人數。

主要風險

  • 手術量——醫院容量與轉診模式決定植入數量。
  • 競爭——Medtronic 與 Abbott 開發競爭性瓣膜平台。
  • 監管與試驗風險——新適應症須試驗成功與審批。
  • 報銷——支付方覆蓋決定影響採用。
  • 製造集中——專業瓣膜生產難以迅速替代。

對標普500的重要性

愛德華是標普500的結構性心臟標的:指數權重 0.08%、醫療保健板塊市值第 #28,是指數對經導管心臟瓣膜的主要敞口。

其手術增長,是心血管介入需求的常設讀數——瓣膜量隨老齡化與診斷變動,往往先於醫院手術收入反映。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 30 日收盤)
財務愛德華生命科學 FY2025 業績(財政年度截至 2025 年 12 月 31 日)、公司簡介來源
板塊分類GICS(醫療保健設備與用品),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

EW

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · EW
Data as of Oct 30, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Delta Air Lines, Inc. (DAL) — XLI Industrials · S&P 500 Profile |達美航空介紹Next · eBay Inc. (EBAY) — XLY Consumer Discretionary · S&P 500 Profile |易貝介紹

Entered 2026-10-31 11:45 · updated 2026-11-14 23:24 · rev 7